Improve Research Reproducibility A Bio-protocol resource
- Home
- Protocols
-
Concise Method
Treatment of Animals With PARP Inhibitor (Olaparib)
Ask a
question
Favorite
Olaparib (AZD2281, Selleck Chemicals) was dissolved in 5.7% DMSO (Rottenberg et al., 2008; Szabova et al., 2014; Henneman et al., 2015). A dose of 50 mg of the Olaparib per kg of body weight per day was injected intraperitoneally into C57BL/6 pregnant mice (12–16 weeks old). Olaparib dosing conditions were established based on the frequency of embryonic lethality and phenotypic penetration of cleft palate (Supplementary Table 1).
Copyright and License information: ©2021 Yamaguchi, Kitami, Wu, He, Wang, Wang and Komatsu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Post a Question0 Q&A
